Literature DB >> 22469175

Chapter 5 itraconazole: comprehensive profile.

Abdullah A Al-Badr, Hussein I El-Subbagh.   

Abstract

Entities:  

Year:  2010        PMID： 22469175     DOI： 10.1016/S1871-5125(09)34005-4

Source DB:  PubMed          Journal:  Profiles Drug Subst Excip Relat Methodol        ISSN： 1871-5125


× No keyword cloud information.
  4 in total

1.  Formation of itraconazole-succinic acid cocrystals by gas antisolvent cocrystallization.

Authors:  Courtney A Ober; Ram B Gupta
Journal:  AAPS PharmSciTech       Date:  2012-10-09       Impact factor: 3.246

2.  Astaxanthin decreases the growth-inhibitory dose of cytarabine and inflammatory response in the acute lymphoblastic leukemia cell line NALM-6.

Authors:  Amirhossein Rastgar; Mahtab Sayadi; Gholamreza Anani-Sarab; Seyed Mehdi Sajjadi
Journal:  Mol Biol Rep       Date:  2022-04-20       Impact factor: 2.742

3.  Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies.

Authors:  Julia Penna-Coutinho; Wilian Augusto Cortopassi; Aline Alves Oliveira; Tanos Celmar Costa França; Antoniana Ursine Krettli
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

4.  Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults.

Authors:  George R Thompson; Phoebe Lewis; Stuart Mudge; Thomas F Patterson; Bruce P Burnett
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.